Clinical trialPhase 2Recruiting
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
A Phase 2 Open-Label, Multi-Center Study of Navlimetostat (BMS-986504) as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTap-5)
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 27 July 2026
- Expected end
- 20 May 2032
- Enrollment
- 254 participants
- Sites
- 58
- Primary outcomes
- Part 1: Number of participants who achieve Objective Response (OR); Part 2: Number of participants with adverse events meeting protocol defined dose limiting toxicities (DLTs) criteria; Part 2: Number of participants with adverse events (AE); Part 2: Number of participants with Serious AEs (SAEs); Part 2: Number of participants with treatment related AEs
- Sponsor
- Industry
- Results posted
- No
- Last update
- 4 November 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try